Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector.
Although several groups have demonstrated that RNA interference, induced by transfection of small interfering RNA (siRNA) duplexes, can protect cells against a viral challenge in culture, this protection is transient. Here, we describe lentivirus expression vectors that can stably express siRNAs at levels sufficient to block virus replication. We have used these vectors to stably express siRNAs specific for the essential human immunodeficiency virus type 1 (HIV-1) Tat transcription factor or specific for a cellular coreceptor, CCR5, that is required for infection by the majority of primary HIV-1 isolates. These lentivirus vectors are shown to protect cells, including primary macrophages, against HIV-1 infection in culture by inducing selective degradation of their target mRNA species. These data suggest that it should be possible to block the expression of specific viral or cellular genes in vivo by using viral vectors to stably express the appropriate siRNAs.
Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina 27710, USA.
Ming-Ta M
MT
Lee
Glen A
GA
Coburn
Myra O
MO
McClure
Bryan R
BR
Cullen
D000998:Antiviral Agents / Q000502:physiology*; D065100:CCR5 Receptor Antagonists; D002478:Cells, Cultured; D015756:Genes, tat; D015316:Genetic Therapy; D005822:Genetic Vectors; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D008264:Macrophages / Q000821:virology*; D034741:RNA, Small Interfering / Q000235:genetics / Q000502:physiology*; D019713:Receptors, CCR5 / Q000235:genetics*; D014779:Virus Replication
D000998:Antiviral Agents; D065100:CCR5 Receptor Antagonists; D034741:RNA, Small Interfering; D019713:Receptors, CCR5